Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

VTYX vs CGEN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGEN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

CGEN Overall Winner 6-Pillar Tally: VTYX 1 – 5 CGEN Matrix Metrics: VTYX 4 – 6 CGEN

As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Ventyx Biosciences, Inc. (VTYX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VTYX carries a Unified Composite Score of 50.4/100 (HOLD) at $14.00 (N/M Forward P/E, 0.0% operating margin), whereas CGEN carries 49.8/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin).

  • Composite vs. Pillar Nuance: While VTYX currently prints a higher short-term Unified Composite Score (50.4/100 HOLD vs. CGEN 49.8/100 HOLD), CGEN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (41.3% vs. 0.0% operating margin) and revenue trajectory (+102.1% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: VTYX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 70.7); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VTYX vs CGEN
VTYX NASDAQ
Ventyx Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$14.00
+0.14% 1D
Market Cap $1.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.07β · 2% Vol
Unified Composite Score
50.4 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 69.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (19.0% over 20 days), RSI 71
RSI-14: 70.7 · SMA20: $13.96 · SMA50: $12.72
CGEN NASDAQ Head-to-Head Winner
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap $193.2M
TTM Revenue $76M
Forward P/E 12.4x
Beta / 30D Vol 1.44β · 62% Vol
Unified Composite Score
49.8 / 100 HOLD
Tech 53.0 Fund 52.0 Flow 55.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $2.02 · SMA50: $2.18

6-Pillar Scorecard Institutional Category Breakdown (VTYX 1 – 5 CGEN)

Columns: Metric · VTYX · CGEN
1. Valuation Multiples CGEN
Forward P/E N/M 12.4x
Trailing P/E N/M 5.2x
PEG Ratio N/M 1.29x
EV / Revenue N/M 2.5x
2. Growth & Scale CGEN
Revenue Growth (YoY) +0.0% +102.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $76M
Market Cap $1.0B $193.2M
3. Profitability & Quality CGEN
Gross Margin N/A 86.2%
Operating Margin 0.0% 41.3%
Net Profit Margin 0.0% 47.9%
Return on Equity (ROE) -45.4% 57.2%
4. Balance Sheet & Cash Flow CGEN
Cash Generation (TTM) N/A $32M EBITDA
Cash Flow Margin N/A 41.9% EBITDA Mgn
Net Cash / Leverage $2.68 Book/Sh · -45.4% ROE $4.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VTYX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 0.5% (<1st %ile) 89.7% (57th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CGEN
OpEx & R&D Intensity N/A 44.9% of Rev ($34M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VTYX (4) vs CGEN (6)
Institutional Metric VTYX CGEN Criterion Row Edge
Market Capitalization
Scale
$1.0B $193.2M Larger Scale VTYX
Trailing P/E Ratio
Valuation
N/M 5.2x Lower Multiple CGEN
Forward P/E Ratio
Valuation
N/M 12.4x Lower Multiple CGEN
Revenue Growth (YoY)
Growth
+0.0% +102.1% Higher Growth CGEN
Operating Margin (TTM)
Profitability
0.0% 41.3% Higher Margin CGEN
Net Profit Margin
Profitability
0.0% 47.9% Higher Margin CGEN
Return on Equity (ROE)
Capital Efficiency
-45.4% 57.2% Higher ROE CGEN
52-Week Range Position
Momentum
55% ($1–$25) 33% ($1–$3) Stronger Trend VTYX
Beta / 30D Volatility
Risk Regime
2.07β · 2% Vol 1.44β · 62% Vol Lower Realized Risk VTYX
Unified Institutional Score
Composite Signal
50.4 / 100 (HOLD) 49.8 / 100 (HOLD) Higher Composite VTYX
Trailing 12M Revenue (USD)
Operating Scale
N/A $76M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 86.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.29x PEG · 2.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($2.68 Book/Sh · -45.4% ROE) $32M EBITDA ($4.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CGEN +8.34 pp
VTYX: +0.36% · CGEN: +8.7%
3M Horizon VTYX +11.79 pp
VTYX: +40.0% · CGEN: +28.21%
6M Horizon VTYX +29.4 pp
VTYX: +51.35% · CGEN: +21.95%
1Y Horizon VTYX +29.4 pp
VTYX: +51.35% · CGEN: +21.95%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VTYX vs CGEN. Trailing 12-month operating profitability (VTYX 0.0% vs CGEN 41.3%) and valuation multiples (VTYX N/M vs CGEN 12.4x Forward P/E) are benchmarked directly in Pillar 4 below.

VTYX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-45.4% · N/M
CGEN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$76M
Gross Margin86.2%
Op. Margin41.3%
ROE / Fwd P/E57.2% · 12.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VTYX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.5%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTYX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CGEN BREAKDOWN
143d in phase · OBV NEUTRAL
Current IV 89.7%
IV Percentile 57th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VTYX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CGEN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $193.2M market capitalization and 41.3% operating margin.
OpEx & R&D Reinvestment 44.9% of Rev ($34M)
90D Engineering Disclosures 0 Published

Investor FAQ VTYX vs CGEN Key Questions & Quantitative Answers

As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Ventyx Biosciences, Inc. (VTYX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VTYX carries a Unified Composite Score of 50.4/100 (HOLD) at $14.00 (N/M Forward P/E, 0.0% operating margin), whereas CGEN carries 49.8/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin). Composite vs. Pillar Nuance: While VTYX currently prints a higher short-term Unified Composite Score (50.4/100 HOLD vs. CGEN 49.8/100 HOLD), CGEN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (41.3% vs. 0.0% operating margin) and revenue trajectory (+102.1% vs. +0.0% YoY). Technical & Structure Timing Caution: VTYX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 70.7); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CGEN leads the Growth & Scale pillar: VTYX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CGEN at +102.1% YoY revenue growth and +0.0% YoY earnings growth on $76M TTM revenue (86.2% gross margin, 41.3% operating margin). On trailing 12-month operating scale, VTYX generates N/A in USD-normalized revenue versus $76M for CGEN. In operating R&D and SG&A reinvestment, VTYX deploys N/A (0 90-day corporate R&D disclosures) versus 44.9% of Rev ($34M) (0 disclosures) for CGEN.

CGEN screens cheaper on headline valuation multiples. VTYX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CGEN trades at 12.4x Forward P/E, 5.2x Trailing P/E, 1.29x PEG, and 2.5x EV/Revenue (41.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTYX (-45.4% ROE) versus CGEN (57.2% ROE) capital efficiency.

In options market volatility and institutional positioning, VTYX carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 2% Vol realized risk). By comparison, CGEN carries 89.7% implied volatility (57th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.